138 related articles for article (PubMed ID: 17163402)
21. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo.
Ribatti D; Guidolin D; Conconi MT; Nico B; Baiguera S; Parnigotto PP; Vacca A; Nussdorfer GG
Oncogene; 2003 Sep; 22(41):6458-61. PubMed ID: 14508526
[TBL] [Abstract][Full Text] [Related]
22. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Nasr M; Selima E; Hamed O; Kazem A
Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
[TBL] [Abstract][Full Text] [Related]
23. The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma.
Li M; Pathak RR; Lopez-Rivera E; Friedman SL; Aguirre-Ghiso JA; Sikora AG
J Vis Exp; 2015 Oct; (104):. PubMed ID: 26484588
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.
Taketomi A
Int J Clin Oncol; 2016 Apr; 21(2):213-218. PubMed ID: 26899258
[TBL] [Abstract][Full Text] [Related]
25. Angiogenesis in hepatocellular carcinoma: an experimental study in the chick embryo chorioallantoic membrane.
Marzullo A; Vacca A; Roncali L; Pollice L; Ribatti D
Int J Oncol; 1998 Jul; 13(1):17-21. PubMed ID: 9625798
[TBL] [Abstract][Full Text] [Related]
26. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
27. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis rhizome in hepatocellular carcinoma.
Tan HY; Wang N; Tsao SW; Zhang Z; Feng Y
Integr Cancer Ther; 2014 Sep; 13(5):425-34. PubMed ID: 24363282
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
Zhang S; Tang D; Zang W; Yin G; Dai J; Sun YU; Yang Z; Hoffman RM; Guo X
Anticancer Res; 2017 Feb; 37(2):465-473. PubMed ID: 28179291
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.
Kuo ZK; Lin MW; Lu IH; Yao HJ; Wu HC; Wang CC; Lin SH; Wu SY; Tong TS; Cheng YC; Yen JH; Ko CH; Chiou SJ; Pan IH; Tseng HW
BMC Complement Altern Med; 2016 Aug; 16():277. PubMed ID: 27502492
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
31. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
32. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
33. Anti-angiogenesis effect of essential oil from Curcuma zedoaria in vitro and in vivo.
Chen W; Lu Y; Gao M; Wu J; Wang A; Shi R
J Ethnopharmacol; 2011 Jan; 133(1):220-6. PubMed ID: 20920565
[TBL] [Abstract][Full Text] [Related]
34. Agrin Mediates Angiogenesis in the Tumor Microenvironment.
Chakraborty S; Njah K; Hong W
Trends Cancer; 2020 Feb; 6(2):81-85. PubMed ID: 32061308
[TBL] [Abstract][Full Text] [Related]
35. The chick chorioallantoic membrane as an in vivo angiogenesis model.
Ponce ML; Kleinmann HK
Curr Protoc Cell Biol; 2003 May; Chapter 19():Unit 19.5. PubMed ID: 18228425
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
Jiang F; Wang X; Liu Q; Shen J; Li Z; Li Y; Zhang J
Toxicol Lett; 2014 Nov; 231(1):55-61. PubMed ID: 25196641
[TBL] [Abstract][Full Text] [Related]
38. The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA; Sun W; Kim R; He AR; Abada PB; Mynderse M; Finn RS
Clin Cancer Res; 2019 Feb; 25(3):912-920. PubMed ID: 30274981
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
